Related Experiment Video
Updated: Feb 14, 2026

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
Published on: October 17, 2017
Blocking Wnt5a signaling decreases CD36 expression and foam cell formation in atherosclerosis
Ian Ackers1, Candice Szymanski2, K Jordan Duckett2
1Heritage Fellow, Translational Biomedical Sciences Program, Ohio University, Athens, Ohio, USA.
Background And Aims:
Wnt5a is a highly studied member of the Wnt family and recently has been implicated in the pathogenesis of atherosclerosis, but its precise role is unknown. Foam cell development is a critical process to atherosclerotic plaque formation. In the present study, we investigated the role of noncanonical Wnt5a signaling in the development of foam cells.
Methods:
Human carotid atherosclerotic tissue and THP-1-derived macrophages were used to investigate the contribution of Wnt5a signaling in the formation of foam cells. Immunohistochemistry was used to evaluate protein expression of scavenger receptors and noncanonical Wnt5a receptors [frizzled 5 (Fz5) and receptor tyrosine kinase-like orphan receptor 2 (Ror2)] in human atherosclerotic macrophages/foam cells. Changes in protein expression in response to Wnt5a stimulation/inhibition were determined by Western blot, and lipid accumulation was evaluated by fluorescent lipid droplet staining.
Results:
Wnt5a (P<.05), Fz5 (P<.01), and Ror2 (P<.01) were significantly expressed in advanced atherosclerotic lesions compared to less advanced lesions (N=10). Wnt5a, Fz5, and Ror2 were expressed in macrophages/foam cells within the plaque. In vitro studies revealed that Wnt5a significantly increased the expression of the lipid uptake receptor CD36 (P<.05) but not the lipid efflux receptor ATP-binding cassette transporter (P>.05). rWnt5a also significantly increased lipid accumulation in THP-1 macrophages (P<.05). Furthermore, inhibition of Wnt5a signaling with Box5 prevented lipid accumulation (P<.01) and prevented CD36 up-regulation (P<.01).
Conclusions:
These results suggest a direct role for Wnt5a signaling in the pathogenesis of atherosclerosis, specifically the accumulation of lipid in macrophages and the formation of foam cells.
Insights
Noncanonical Wnt5a signaling promotes atherosclerosis by increasing lipid accumulation in macrophages, leading to foam cell formation. Inhibition of Wnt5a signaling reduces this lipid uptake and foam cell development.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Cell Biology
Background:
- Atherosclerosis pathogenesis involves foam cell development.
- The precise role of Wnt5a in atherosclerosis is not fully understood.
- Noncanonical Wnt5a signaling is investigated for its role in foam cell formation.
Purpose of the Study:
- To investigate the role of noncanonical Wnt5a signaling in foam cell development.
- To determine Wnt5a's contribution to lipid accumulation in macrophages.
Main Methods:
- Human carotid atherosclerotic tissue and THP-1 macrophages were utilized.
- Immunohistochemistry and Western blot assessed protein expression of Wnt5a, Fz5, Ror2, CD36, and ABC transporter.
- Lipid accumulation was quantified using fluorescent lipid droplet staining.
Main Results:
- Wnt5a, Frizzled 5 (Fz5), and Receptor tyrosine kinase-like orphan receptor 2 (Ror2) were significantly expressed in advanced atherosclerotic lesions.
- Wnt5a stimulation increased CD36 expression and lipid accumulation in macrophages.
- Inhibition of Wnt5a signaling with Box5 reduced lipid accumulation and CD36 up-regulation.
Conclusions:
- Wnt5a signaling plays a direct role in atherosclerosis pathogenesis.
- Wnt5a promotes lipid accumulation in macrophages, contributing to foam cell formation.
- Targeting Wnt5a signaling may offer therapeutic potential for atherosclerosis.
Related Concept Videos
What is Cell Signaling?
Decreasing Function
Decreased Body Temperature
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Cell Specific Gene Expression
Atherosclerosis III: Management

